Abstract：
Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit-risk balance of these therapies could differ for dialysis patients compared with the general population. This review article focuses on the bleeding risk associated with the use of heparin, antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients receiving hemodialysis.
摘要：
心血管疾病在透析患者中非常普遍。对于这些疾病,抗血小板和抗血栓治疗，包括肝素，维生素K拮抗剂，和直接口服抗凝剂，正在使用。然而,透析患者与普通人群相比,这些治疗的获益-风险平衡可能有所不同.这篇综述的重点是与使用肝素相关的出血风险，抗血小板,维生素K拮抗剂，血液透析患者的直接口服抗凝剂。
